Mesothelioma Clinical Trial Pipeline 2026: 30+ Studies Reshaping Treatment After Nivolumab

The mesothelioma clinical trial landscape shifted permanently in 2021 when CheckMate 743 established nivolumab plus ipilimumab as the first approved immunotherapy regimen for unresectable pleural mesothelioma. The February 2026 five-year update sealed its status: 14% five-year overall survival with immunotherapy versus 6% with chemotherapy. For patients with non-epithelioid disease, the five-year OS gap was even wider — 12% versus 1%.

But immunotherapy is now the starting line, not the finish line. More than 30 active clinical trials are currently recruiting mesothelioma patients, testing treatments that work by entirely different mechanisms — from engineered immune cells to cancer vaccines to targeted molecular inhibitors. This article covers the most important trials in each category and what patients need to know to access them. For a full list of currently enrolling studies, see the Clinical Trials resource at WikiMesothelioma.

What Are the Key Facts About the 2026 Mesothelioma Clinical Trial Pipeline?

• The 2026 pipeline includes 30+ active recruiting trials across immunotherapy combinations, targeted therapy, CAR-T, cancer vaccines, antibody-drug conjugates, and radiation
• CheckMate 743 five-year data (February 2026): 14% OS with nivolumab + ipilimumab vs. 6% with chemotherapy (HR 0.74)
• Non-epithelioid patients showed the largest benefit: 12% vs. 1% five-year OS (HR 0.48)
• The MSK CAR-T Phase 1 predecessor trial showed 72% ORR in mesothelioma subgroup with median OS 23.9 months
• eVOLVE-Meso (NCT06097728) enrolls 825 patients testing volrustomig (PD-L1/CTLA-4 bispecific antibody)
• BAP1 gene loss affects 60–80% of mesothelioma cases and opens EZH2 inhibitor trial eligibility
• MTAP deletion affects approximately 25% of mesothelioma cases; MRTX1719 Phase 1 is actively recruiting
• UV1 telomerase vaccine: FDA Fast Track Designation (February 2024); Phase II showed 31% ORR vs. 16% with immunotherapy alone
• The NCI TNhYP218 CAR-T trial (launched July 2025) is conducted at no cost to participants at the NIH Clinical Center
• MARS 2 (2024): EPD surgery plus chemotherapy is inferior to chemotherapy alone (19.3 vs. 24.8 months); standard of care no longer includes extended surgery for most patients
• Sacituzumab govitecan (TROP-2 ADC) and CT-95 are in Phase 2 and Phase 1 trials at Memorial Sloan Kettering
• Proton beam therapy: HIT-Meso Phase III (NCT05655078) recruits 148 patients at 18–20 UK centers through March 2027

What Did CheckMate 743's Five-Year Data Actually Confirm?

The February 2026 publication of CheckMate 743's five-year outcomes — the longest follow-up ever reported for first-line immunotherapy in pleural mesothelioma — changed how oncologists counsel patients at diagnosis.

At a median follow-up of 66.8 months, nivolumab plus ipilimumab achieved an overall survival hazard ratio of 0.74 (95% CI 0.62–0.88). The five-year survival rate of 14% means roughly 1 in 7 patients treated with dual checkpoint blockade is alive five years later — a result that would have seemed impossible when mesothelioma's median survival on chemotherapy was approximately 12 months.

The benefit was not distributed evenly. Patients with non-epithelioid mesothelioma (sarcomatoid or biphasic cell type) showed the most dramatic improvement: 12% five-year OS with immunotherapy versus 1% with chemotherapy (HR 0.48). This subgroup had historically been considered the hardest to treat, making the immunotherapy benefit especially significant for legal and medical guidance.

"These five-year results establish immunotherapy as the anchor of mesothelioma treatment — but they also define the ceiling we need to break through. The patients not in that 14% are exactly who the next generation of trials is designed for."

— David Foster, 18+ Years Mesothelioma Advocacy | Host of MESO Podcast

For patients and families, the practical implication is direct: immunotherapy extends life meaningfully for some patients, but most will eventually need a second option. The pipeline below is built to address exactly that need. For an overview of how current treatment compares to pipeline options, the Treatment Options page at WikiMesothelioma provides a continuously updated comparison.

What Is eVOLVE-Meso and Why Does It Matter in 2026?

The most consequential actively enrolling mesothelioma trial of 2026 is eVOLVE-Meso (NCT06097728) — a pivotal Phase III study testing volrustomig, a novel bispecific antibody that simultaneously blocks both PD-L1 and CTLA-4 on a single molecule.

Where CheckMate 743 used two separate drugs (nivolumab targeting PD-1, ipilimumab targeting CTLA-4), volrustomig delivers both mechanisms in one agent. The trial enrolls 825 patients globally across two arms: volrustomig plus chemotherapy versus the current standard of care (either nivolumab plus ipilimumab or chemotherapy, per physician choice).

eVOLVE-Meso addresses a question CheckMate 743 did not answer: whether combining immunotherapy with chemotherapy from the start outperforms immunotherapy alone. The DREAM3R trial (durvalumab plus chemotherapy, October 2025) produced numerically improved but statistically inconclusive overall survival (21 vs. 18 months, HR 0.92). eVOLVE-Meso, with 825 patients, is powered to deliver a definitive answer. Patients interested in enrollment should ask their oncologist about eligibility at the trial's academic center sites across the United States, Europe, and Australia.

How Does CAR-T Cell Therapy Work for Mesothelioma?

CAR-T (chimeric antigen receptor T-cell) therapy takes a patient's own immune cells, genetically engineers them to recognize and destroy cancer cells, then reinfuses them. In mesothelioma, the primary target is mesothelin — a protein overexpressed in approximately 70–80% of epithelioid mesotheliomas.

The foundational Phase 1 trial at Memorial Sloan Kettering (NCT02414269) provided the most compelling results to date. Among 18 mesothelioma patients treated with intrapleural mesothelin-directed CAR-T plus pembrolizumab: median overall survival was 23.9 months, with a 1-year OS rate of 83%. In the 11-patient mesothelioma subgroup, the objective response rate was 72%.

The current MSK Phase 1 trial (NCT04577326) uses an updated design — M28z1XXPD1DNR — incorporating a dominant negative PD-1 receptor to resist the immunosuppressive tumor microenvironment that typically exhausts CAR-T cells inside solid tumors. Treatment is delivered intrapleurally (directly into the pleural cavity), concentrating the therapy at the tumor site while reducing systemic toxicity.

Who Qualifies for the MSK CAR-T Trial?

• Epithelioid or biphasic mesothelioma
• At least 10% mesothelin expression by IHC
• At least one prior treatment
• Adequate organ function; no serious active autoimmune disease
• Location: Memorial Sloan Kettering Cancer Center, New York, NY

A separate NCI trial (TNhYP218, launched July 2025) uses T naive/stem cell memory-derived CAR-T cells with superior longevity. The NCI trial is conducted at no cost to participants at the NIH Clinical Center in Bethesda, Maryland — a significant access advantage. For information on academic cancer centers running these trials, the Mesothelioma Treatment Centers directory at WikiMesothelioma lists facilities by state with contact details.

"CAR-T is not a theoretical breakthrough anymore — there are two recruiting trials now, one of which is federally funded and costs patients nothing. The barrier is awareness, not access."

— David Foster, 18+ Years Mesothelioma Advocacy | Host of MESO Podcast

What Are EZH2 Inhibitors and Who Are They For?

One of the most targeted approaches in the 2026 pipeline exploits a genetic vulnerability present in the majority of mesothelioma cases.

BAP1 (BRCA1-associated protein 1) is a tumor suppressor gene mutated or deleted in approximately 60–80% of mesothelioma cases. When BAP1 is lost, cancer cells become abnormally dependent on the EZH2 enzyme for survival. This dependency creates synthetic lethality — inhibiting EZH2 selectively kills BAP1-deficient cancer cells while largely sparing normal tissue.

Two EZH2 inhibitors are in active trials for BAP1-deficient mesothelioma in 2026:

Tazemetostat (NCT02860286) — A Phase 2 trial at Dana-Farber Cancer Institute testing 800 mg twice daily in relapsed/refractory BAP1-deficient mesothelioma. Tazemetostat is already FDA-approved for BAP1/INI1-related epithelioid sarcoma, establishing a regulatory pathway that similar drugs lack.

Tulmimetostat/CPI-0209 (NCT04104776, Cohort M5) — A next-generation dual EZH2/EZH1 inhibitor with potentially broader chromatin remodeling effects. Preliminary ASCO 2024 data from the mesothelioma cohort (n=29 evaluable) showed 1 partial response and 7 stable disease cases — sufficient to trigger Stage 2 expansion. Enrollment is ongoing at Emory Winship, University of Chicago, Dana-Farber, Mass General, and other centers.

"BAP1 testing should be part of every mesothelioma patient's standard molecular workup. It is one IHC stain — a straightforward test. Without it, patients with BAP1 loss may never know they qualify for a trial specifically designed for their tumor subtype."

— David Foster, 18+ Years Mesothelioma Advocacy | Host of MESO Podcast

What Cancer Vaccines Are Being Tested for Mesothelioma?

The 2026 pipeline includes two vaccine approaches that have reached advanced clinical stages:

UV1 Telomerase Vaccine: UV1 targets telomerase — an enzyme present in approximately 85% of cancer cells but largely absent from normal tissue. The Phase II NIPU trial showed UV1 combined with nivolumab plus ipilimumab achieved a 31% objective response rate versus 16% with immunotherapy alone, with 27% improved survival in a subgroup analysis. UV1 received FDA Fast Track Designation in February 2024. A Phase III trial is in planning.

DENIM Dendritic Cell Vaccine: The DENIM Phase II/III trial (dendritic cells loaded with allogeneic tumor lysate — MesoPher) failed to meet its primary OS endpoint in 2024, reporting 16.8 versus 18.3 months (HR 1.10, p=0.62). This effectively closed this specific allogeneic lysate approach, though research into personalized neoantigen vaccines continues at several centers.

The divergent UV1 and DENIM results illustrate an important principle: not all cancer vaccines are equivalent. UV1 targets a universal cancer enzyme (telomerase) present in the vast majority of tumor cells; DENIM used non-personalized lysate material. The specificity and universality of the immune target appears to be a critical determinant of vaccine efficacy in mesothelioma.

What Are Antibody-Drug Conjugates and Which ADCs Are Being Tested?

An antibody-drug conjugate (ADC) functions as a guided missile: a monoclonal antibody that finds a specific protein on tumor cells and delivers a chemotherapy payload directly to them, reducing systemic toxicity compared to conventional chemotherapy.

The most active ADC in the mesothelioma pipeline is sacituzumab govitecan (NCT06477419) — a TROP-2-targeted ADC in Phase 2 at Memorial Sloan Kettering. TROP-2 is expressed on many solid tumors, and sacituzumab govitecan is already FDA-approved for triple-negative breast cancer and urothelial cancer, providing a safety and pharmacology baseline that accelerates mesothelioma trial design.

A prior trial of anetumab ravtansine (anti-mesothelin ADC, NCT03126630) in combination with pembrolizumab showed a disease control rate of 67% in the combined Phase 1 and Phase 2 population — but did not produce statistically significant improvement in PFS versus pembrolizumab alone. An important finding: elevated baseline soluble mesothelin was associated with inferior outcomes, suggesting soluble MSLN may neutralize mesothelin-targeted therapies. Future ADC trial eligibility will likely incorporate baseline soluble mesothelin as a selection criterion.

What Is MTAP Deletion and Why Does It Open New Trial Options?

Approximately 25% of mesothelioma cases carry a deletion of the MTAP gene. This deletion causes accumulation of a substrate molecule called MTA, which partially inhibits an enzyme called PRMT5. A novel drug, MRTX1719, is designed to fully block PRMT5 selectively in cells with MTA accumulation — creating a targeted kill mechanism in MTAP-deleted tumor cells while sparing normal tissue.

The Phase 1 trial of MRTX1719 (NCT05094336) is actively enrolling patients with MTAP-deleted solid tumors, including mesothelioma. Like BAP1, MTAP deletion status requires biomarker testing (via next-generation sequencing) that should be ordered at diagnosis.

A separate molecular target, the YAP/TEAD signaling pathway, is being addressed by SW-682 (Phase 1a/1b at multiple centers). YAP/TEAD drives aggressive tumor behavior in mesothelioma and has historically been considered undruggable — SW-682 represents the first clinical-stage agent to directly block this pathway.

How Should Patients Use This Pipeline Information?

The trials described above are not theoretical — they are active, recruiting studies at identifiable institutions. But accessing them requires proactive steps that most community oncologists will not initiate without an explicit patient request.

Five practical steps for patients and caregivers:

• Request complete biomarker testing at diagnosis: BAP1 (IHC and sequencing), MTAP (NGS or FISH), mesothelin expression (IHC), PD-L1 (IHC), and TMB. Each result opens or closes specific trial options.
• Search ClinicalTrials.gov for your molecular profile: Filter by condition (mesothelioma), status (recruiting), and location. The Clinical Trials page at WikiMesothelioma also maintains a curated list by treatment category.
• Contact trial coordinators directly: Most trials allow patient self-referral. You do not need a physician referral to inquire about eligibility.
• Ask about the NCI trial at no cost: The TNhYP218 CAR-T trial at the NIH Clinical Center covers treatment costs and may cover some travel.
• Seek a consultation at an NCI-designated cancer center: Community oncologists may be unaware of all active trials. A second opinion at a National Cancer Institute-designated center can identify options that local providers have not considered.

If you are also exploring legal compensation options — asbestos trust funds, VA benefits, or litigation — our free case assessment can identify which pathways apply to your exposure history. Understanding both your medical and financial options simultaneously allows families to plan more effectively. Our attorneys have helped mesothelioma patients access asbestos trust fund compensation while they navigate their treatment decisions.

"I have spoken with families who were told there were no more options — and we found an active trial at an NCI center that their local hospital didn't know about. The pipeline exists. The barrier is awareness."

— David Foster, 18+ Years Mesothelioma Advocacy | Host of MESO Podcast

What Are the Most Common Questions About the 2026 Mesothelioma Clinical Trial Pipeline?

What new mesothelioma treatments are available in clinical trials in 2026?

In 2026, more than 30 active clinical trials are recruiting mesothelioma patients. Key areas include CAR-T cell therapy at Memorial Sloan Kettering (NCT04577326) and the NCI (TNhYP218, launched July 2025), EZH2 inhibitors for BAP1-deficient patients (tazemetostat NCT02860286, tulmimetostat NCT04104776), the pivotal eVOLVE-Meso Phase III trial of volrustomig enrolling 825 patients globally, the UV1 telomerase cancer vaccine (FDA Fast Track designated February 2024), sacituzumab govitecan (TROP-2 ADC in Phase 2), and proton beam therapy (HIT-Meso Phase III). Many of these trials specifically target patients who have progressed after nivolumab plus ipilimumab.

What did the CheckMate 743 five-year update confirm?

The February 2026 five-year update confirmed that nivolumab plus ipilimumab achieves a 5-year overall survival rate of 14% versus 6% with chemotherapy (HR 0.74) at a median follow-up of 66.8 months — the longest ever reported for first-line immunotherapy in pleural mesothelioma. For non-epithelioid patients the benefit was most dramatic: 12% versus 1% five-year OS (HR 0.48). This establishes the approximately 86% of patients who will eventually progress as the target population for the current clinical trial pipeline.

Who qualifies for mesothelioma CAR-T cell therapy trials in 2026?

The MSK CAR-T trial (NCT04577326) requires epithelioid or biphasic mesothelioma with at least 10% mesothelin expression by IHC and at least one prior treatment. The NCI TNhYP218 trial requires greater than 50% mesothelin-expressing tumor cells and at least one prior treatment — and is conducted at no cost. EVEREST-2 requires both mesothelin and EpCAM expression as a logic-gated safety feature. All trials require adequate organ function and no serious active autoimmune disease.

What is BAP1 and why does it matter for trial eligibility?

BAP1 (BRCA1-associated protein 1) is mutated or deleted in approximately 60 to 80 percent of mesothelioma cases. Its loss creates dependency on EZH2, making BAP1-deficient tumors potentially responsive to EZH2 inhibitors like tazemetostat (NCT02860286) and tulmimetostat (NCT04104776, Cohort M5). BAP1 testing is a simple IHC stain that should be ordered at diagnosis. Without it, most patients will never know they qualify for a trial designed for their specific tumor subtype.

What is the eVOLVE-Meso trial?

eVOLVE-Meso (NCT06097728) is a pivotal Phase III trial testing volrustomig — a bispecific antibody blocking both PD-L1 and CTLA-4 simultaneously — plus chemotherapy versus current standard of care. It enrolls 825 patients globally, making it the largest mesothelioma Phase III trial of 2026. Unlike CheckMate 743, eVOLVE-Meso combines immunotherapy with chemotherapy from the start, testing whether this triple approach outperforms immunotherapy alone.

Can mesothelioma patients access the NCI CAR-T trial at no cost?

Yes. The NCI TNhYP218 CAR-T trial launched July 2025 at the NIH Clinical Center in Bethesda, Maryland is conducted at no cost to participants, with possible travel cost coverage. The trial uses T naive/stem cell memory-derived CAR-T with superior longevity. Eligibility requires greater than 50% mesothelin expression and at least one prior treatment. Each treatment cycle requires at least 14 days of hospitalization. Patients can self-refer by contacting the NCI's Mesothelin-targeted Cell Therapy program directly.

References

1. Scherpereel A, et al. "Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab vs Chemotherapy in Unresectable Pleural Mesothelioma." Journal of Clinical Oncology, February 2026. ASCO Post coverage.
2. Szlosarek PW, et al. "The ATOMIC-Meso Randomized Clinical Trial." JAMA Oncology, 2024;10(4):475–483. PMID: 38358753.
3. Zhang AL, Hsu ML. "Immunotherapy advances in pleural mesothelioma." Therapeutic Advances in Medical Oncology, 2026. PMC12905100.
4. Cardillo G, et al. "Malignant Pleural Mesothelioma: A 2025 Update." Journal of Clinical Medicine, February 2025. PMC11818641.
5. Mansfield AS, Hassan R, et al. "Randomized Trial of Anetumab Ravtansine and Pembrolizumab for Mesothelioma." Lung Cancer, August 2024. PMC11416719.
6. Reuss JE, et al. "Perioperative nivolumab ± ipilimumab in resectable diffuse pleural mesothelioma." Nature Medicine, December 2025;31(12):4097–4108. doi:10.1038/s41591-025-03958-3.
7. "Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma." Cancers, December 2025. PMC12939869.
8. "PD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma." Cells, January 2026;15(2):183. PMID: 41597257.
9. "Current landscape of CAR-T cell therapy in mesothelioma." Frontiers in Oncology, September 2025. PMC12440771.
10. "EVEREST-2: Phase 1/2 study of A2B694 mesothelin logic-gated CAR-T." Journal of Clinical Oncology, 2024;42(16_suppl):TPS2699. doi:10.1200/JCO.2024.42.16_suppl.TPS2699.
11. NCT04577326 — MSK Mesothelin CAR-T Phase I. ClinicalTrials.gov.
12. NCT06097728 — eVOLVE-Meso Phase III. ClinicalTrials.gov.
13. "Targeting Telomerase in Cancer: Vaccine-Based Strategies." Diseases, February 2026. PMC12939409.
14. "Phase 2 Study of Olaparib in Malignant Mesothelioma." JTO Clinical and Research Reports, September 2021. PMC8502774.
15. Clinical Trials — WikiMesothelioma.
16. Treatment Options — WikiMesothelioma.
17. Mesothelioma Treatment Centers — WikiMesothelioma.